Neurodegenerative disease model construction method based on iPSC

By obtaining somatic cells from the patient's body and reprogramming them into iPSCs, differentiating them into nerve cells, combining high-throughput screening and CRISPR technology, an accurate neurodegenerative disease model was constructed, solving the problem that traditional methods were difficult to simulate the complexity of the disease, and realizing the Rapid evaluation of drug efficacy and genetic function research has promoted the research and treatment process of neurodegenerative diseases.

CN118995631APending Publication Date: 2024-11-22SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI +1
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410948776.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Traditional animal models and in vitro research methods are difficult to fully simulate the complexity and individual differences of human neurodegenerative diseases, resulting in a low conversion rate of research results and clinical applications.

Method used

By obtaining somatic cells from patients with neurodegenerative diseases, reprogramming into iPSCs, and differentiating into neural progenitor cells and specific types of nerve cells, combining high-throughput screening technology and CRISPR/Cas9 gene editing technology, we can build accurate Disease models are used to simulate pathological characteristics and to evaluate the efficacy of drug candidates.

Benefits of technology

It has achieved accurate simulation of the pathological characteristics of neurodegenerative diseases in vitro, quickly evaluate the efficacy of candidate drugs and study gene functions, reveal the molecular mechanisms of the disease, accelerate the development of new drugs, provide important tools for the development of personalized treatment strategies, and overcome traditional models limitations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995631A_ABST
    Figure CN118995631A_ABST
Patent Text Reader

Abstract

The invention discloses a method for constructing a neurodegenerative disease model based on iPSCs (induced pluripotent stem cells), and provides a method for constructing a neurodegenerative disease model based on iPSCs (induced pluripotent stem cells), which comprises the following steps: acquiring skin fibroblasts or blood cells of a patient, converting the skin fibroblasts or blood cells into iPSCs (induced pluripotent stem cells) by using a reprogramming technology, and redifferentiating the iPSCs into neural progenitor cells and specific types of nerve cells. The pathological characteristics of neurodegenerative diseases can be accurately simulated in vitro. Meanwhile, by combining a high-throughput screening technology and a CRISPR / Cas9 gene editing technology, the curative effect of candidate drugs can be rapidly evaluated, gene functions can be rapidly researched, the molecular mechanism of diseases is disclosed, the research and development process of new drugs is accelerated, and an important tool is provided for developing personalized treatment strategies. The limitation of a traditional model is overcome, and the research and treatment of neurodegenerative diseases are facilitated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of neurodegenerative disease model construction, and more specifically, to a method for constructing a neurodegenerative disease model based on iPSC. Background Art

[0002] Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, pose a serious threat to human health and currently lack effective treatments. Traditional animal models and in vitro research methods have significant limitations and are unable to fully simulate the complexity and individual differences of human diseases, resulting in a low conversion rate of research results to clinical applications.

[0003] In recent years, the development of induced pluripotent stem cell (iPSCs) technology has provided new possibilities for studying human diseases. By reprogramming the patient's somatic cells into iPSCs and further differentiating them into neural cells, researchers can reproduce the patient's neuropathological process in vitro. This method can not only simulate disease characteristics more accurately, but also use patient-specific cells to develop personalized treatment strategies. However, how to effectively construct and utilize these iPSCs-based disease models remains an urgent problem to be solved.

[0004] Therefore, in response to the above technical problems, it is necessary to provide a method for constructing a neurodegenerative disease model based on iPSC. Summary of the invention

[0005] The purpose of the present invention is to provide a method for constructing a neurodegenerative disease model based on iPSC to solve the above problems.

[0006] In order to achieve the above purpose, the technical solution provided by an embodiment of the present invention is as follows:

[0007] A method for constructing a neurodegenerative disease model based on iPSC, comprising:

[0008] S1: Obtaining somatic cells from patients with neurodegenerative diseases;

[0009] S2: reprogramming the somatic cells into iPSCs;

[0010] S3: amplifying and purifying the iPSCs;

[0011] S4: differentiating the iPSCs into neural progenitor cells (NPCs);

[0012] S5: further differentiating the NPCs into specific types of neural cells;

[0013] S6: verify the type and characteristics of the neural cells;

[0014] S7: Observe and analyze disease-related phenotypic changes in the neural cells.

[0015] As a further improvement of the present invention, the somatic cells obtained in step S1 are any one of skin fibroblasts or blood cells.

[0016] As a further improvement of the present invention, in step S2, somatic cells are reprogrammed into iPSCs by introducing OCT4, SOX2, KLF4 and c-MYC reprogramming factors.

[0017] As a further improvement of the present invention, the reprogramming factors are introduced into the somatic cells via viral vectors or non-viral methods.

[0018] As a further improvement of the present invention, in step S4, iPSCs are differentiated into NPCs by adding neurotrophic factors to the culture medium or forming embryoid bodies through suspension culture.

[0019] As a further improvement of the present invention, in step S5, NPCs are differentiated into dopaminergic neurons, motor neurons or astrocytes by regulating the components of the culture medium and adding specific growth factors.

[0020] As a further improvement of the present invention, in step S6, the type and characteristics of the neural cells are verified by immunofluorescence staining, RT-PCR and Western blot.

[0021] As a further improvement of the present invention, in step S7, the functional characteristics of the nerve cells are evaluated by electrophysiological recording, calcium imaging and synaptic function detection.

[0022] As a further improvement of the present invention, it also includes the step of evaluating multiple candidate drugs in the constructed disease model by high-throughput screening technology to identify potential therapeutic drugs.

[0023] As a further improvement of the present invention, it also includes using CRISPR / Cas9 gene editing technology to knock out, knock in or point mutate specific genes in the nerve cells to study gene functions with high precision and explore the molecular mechanisms of neurodegenerative diseases.

[0024] Compared with the prior art, the advantages of the present invention are:

[0025] This protocol proposes a method for constructing a neurodegenerative disease model based on iPSCs. By obtaining the patient's skin fibroblasts or blood cells and converting them into iPSCs using reprogramming technology, and then differentiating them into neural progenitor cells and specific types of neural cells, it can accurately simulate the pathological characteristics of neurodegenerative diseases in vitro. At the same time, combined with high-throughput screening technology and CRISPR / Cas9 gene editing technology, it can quickly evaluate the efficacy of candidate drugs and study gene functions, reveal the molecular mechanism of the disease, accelerate the process of new drug development, and provide important tools for the development of personalized treatment strategies. It overcomes the limitations of traditional models and is conducive to the research and treatment of neurodegenerative diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 This is a schematic diagram of a method for constructing an iPSC-based neurodegenerative disease model of the present invention. DETAILED DESCRIPTION

[0027] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention; it is obvious that the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments, and all other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention without making creative work are within the scope of protection of the present invention.

[0028] Example:

[0029] See also Figure 1 , a method for constructing a neurodegenerative disease model based on iPSC, comprising:

[0030] S1: Obtaining somatic cells from patients with neurodegenerative diseases;

[0031] S2: Reprogramming somatic cells into iPSCs;

[0032] S3: iPSCs expansion and purification;

[0033] S4: Differentiation of iPSCs into neural progenitor cells (NPCs);

[0034] S5: Further differentiation of NPCs into specific types of neural cells;

[0035] S6: Verify the types and characteristics of neural cells;

[0036] S7: Observe and analyze disease-associated phenotypic changes in neural cells.

[0037] Among them, this scheme proposes a method for constructing a neurodegenerative disease model based on iPSCs. By obtaining the patient's skin fibroblasts or blood cells and converting them into iPSCs using reprogramming technology, and then differentiating them into neural progenitor cells and specific types of neural cells, it can accurately simulate the pathological characteristics of neurodegenerative diseases in vitro. At the same time, combined with high-throughput screening technology and CRISPR / Cas9 gene editing technology, it can quickly evaluate the efficacy of candidate drugs and study gene functions, reveal the molecular mechanism of the disease, accelerate the process of new drug development, and provide important tools for the development of personalized treatment strategies. It overcomes the limitations of traditional models and is conducive to the research and treatment of neurodegenerative diseases.

[0038] The somatic cells obtained in step S1 are either skin fibroblasts or blood cells.

[0039] Among them, the somatic cells obtained in step S1 can be any one of skin fibroblasts or blood cells. Skin fibroblasts (usually obtained by skin biopsy) and blood cells (generally obtained by venous blood drawing) are both common and easily accessible somatic cell types. Skin fibroblasts have become the preferred material in induced pluripotent stem cell (iPSCs) reprogramming research due to their stability and ease of operation in in vitro culture. Blood cells, especially peripheral blood mononuclear cells (PBMCs), have become another important source because of their relatively non-invasive acquisition process and less burden on patients. Through appropriate reprogramming technology, these somatic cells can be converted into pluripotent iPSCs for subsequent construction and research of neurodegenerative disease models.

[0040] In step S2, somatic cells are reprogrammed into iPSCs by introducing OCT4, SOX2, KLF4 and c-MYC reprogramming factors.

[0041] In step S2, somatic cells are reprogrammed into induced pluripotent stem cells (iPSCs) by introducing reprogramming factors OCT4, SOX2, KLF4 and c-MYC. The above reprogramming factors are key transcription factors that can reactivate the pluripotency gene network in somatic cells and return somatic cells to a pluripotent state.

[0042] Specifically, OCT4 and SOX2 are core factors for maintaining the pluripotent state, KLF4 can promote cell proliferation and maintain the self-renewal ability of stem cells, and c-MYC enhances the metabolic activity and proliferation ability of cells. Usually, these factors can be introduced into somatic cells through viral vectors (such as lentivirus or retrovirus) or non-viral methods (such as mRNA transfection or small molecule compounds). Under the joint action of these factors, somatic cells are reprogrammed into iPSCs, which show similar pluripotency and self-renewal ability to embryonic stem cells, providing a basis for the subsequent construction of neurodegenerative disease models.

[0043] Reprogramming factors are introduced into somatic cells using viral vectors or non-viral methods.

[0044] Among them, the reprogramming factors are introduced into somatic cells through viral vectors or non-viral methods. The viral vector method includes the use of lentivirus, retrovirus and other vectors, which can efficiently integrate the gene sequence of the reprogramming factors into the genome of somatic cells, thereby driving the continuous expression of these factors and achieving cell reprogramming.

[0045] Since viral vectors may cause genomic instability and potential safety issues, non-viral methods, including the use of mRNA transfection, protein transduction, liposome-mediated gene transfection, and small molecule compounds, can induce the expression of reprogramming factors without changing the cell genome, reducing the risk of genomic integration. Through these technical means, the reprogramming factors OCT4, SOX2, KLF4, and c-MYC are effectively introduced into somatic cells, initiating the reprogramming process and converting somatic cells into induced pluripotent stem cells (iPSCs) with pluripotency.

[0046] In step S4, iPSCs are differentiated into NPCs by adding neurotrophic factors to the culture medium or forming embryoid bodies through suspension culture.

[0047] Among them, in step S4, induced pluripotent stem cells (iPSCs) are differentiated into neural progenitor cells (NPCs) by adding neurotrophic factors to the culture medium or forming embryoid bodies through suspension culture. Specifically, neurotrophic factors such as Noggin, SB431542, BDNF (brain-derived neurotrophic factor), and GDNF (glial cell-derived neurotrophic factor) can be added to the culture medium to promote the differentiation of iPSCs into neural progenitor cells, and promote the selective differentiation of the neural lineage by regulating cell signaling pathways.

[0048] Another method is to form embryoid bodies through suspension culture. In this method, iPSCs are cultured in suspension to form three-dimensional aggregates, which can spontaneously differentiate into structures containing neural progenitor cells under appropriate culture conditions. Subsequently, neural progenitor cells in embryoid bodies can be further isolated and purified through selective culture conditions.

[0049] The goal is to effectively guide the differentiation of pluripotent iPSCs into NPCs with a specific fate, laying the foundation for subsequent neural cell differentiation and the construction of neurodegenerative disease models.

[0050] In step S5, NPCs are differentiated into dopaminergic neurons, motor neurons or astrocytes by regulating the composition of the culture medium and adding specific growth factors.

[0051] In step S5, the neural progenitor cells (NPCs) are differentiated into dopaminergic neurons, motor neurons or astrocytes by regulating the composition of the culture medium and adding specific growth factors. The specific operation is as follows:

[0052] Dopaminergic neurons are cultured with growth factors such as SHH (Sonic Hedgehog), FGF8 (fibroblast growth factor 8), and GDNF (glial cell-derived neurotrophic factor), which work together to promote the differentiation of NPCs into dopaminergic neurons;

[0053] Motor neurons use RA (retinoic acid) and SHH factors, which can effectively induce NPCs to differentiate into motor neurons;

[0054] Astrocytes: Adding growth factors such as CNTF (ciliary neurotrophic factor) and BMP (bone morphogenetic protein) to the culture medium can promote the differentiation of NPCs into astrocytes. Astrocytes play a role in supporting and protecting neurons in the nervous system and play an important role in the pathological mechanism of many neurodegenerative diseases.

[0055] By precisely regulating the composition of the culture medium and adding different growth factors, NPCs can be effectively differentiated into the required specific neural cell types, which not only provides a diverse cellular basis for constructing different types of neurodegenerative disease models, but also lays the foundation for studying the pathogenesis of these diseases and screening potential therapeutic drugs.

[0056] In step S6, the types and characteristics of neural cells are verified by immunofluorescence staining, RT-PCR and Western blot.

[0057] Among them, immunofluorescence staining is used to detect the presence and location of specific proteins in cells. By using specific antibodies against neural cell markers (such as NeuN, MAP2, TH, GFAP, etc.), it can be confirmed whether the cells have differentiated into the target neural cell type (such as dopaminergic neurons, motor neurons or astrocytes). Fluorescently labeled secondary antibodies are combined with primary antibodies, and observation under a fluorescence microscope can intuitively display the type and characteristics of cells.

[0058] RT-PCR is used to detect and quantify the mRNA expression level of specific genes. By extracting RNA from nerve cells and using specific primers to amplify the cDNA of target genes (such as dopaminergic neuron marker gene TH, motor neuron marker gene ChAT, astrocyte marker gene GFAP, etc.), it can be confirmed whether these genes are expressed in differentiated nerve cells.

[0059] Western blot is used to detect and quantify the expression of specific proteins. Proteins from nerve cells are extracted and separated by SDS-PAGE electrophoresis, then transferred to a membrane and detected using specific antibodies against the target protein. Western blot can verify whether specific marker proteins (such as TH protein of dopaminergic neurons, ChAT protein of motor neurons, GFAP protein of astrocytes, etc.) are expressed in nerve cells, thereby further confirming the differentiation state and characteristics of the cells.

[0060] In step S7, the functional properties of the neurons are evaluated by electrophysiological recording, calcium imaging, and synaptic function testing.

[0061] Among them, the patch clamp technique uses patch clamp technology to record the electrical activity of a single nerve cell. The action potential, synaptic current and ion channel activity of nerve cells can be measured to evaluate the excitability and electrical conduction characteristics of nerve cells. By analyzing the frequency, amplitude and duration of the action potential, the functional state and health of nerve cells can be determined.

[0062] Calcium indicator staining uses calcium indicators (such as Fura-2, Fluo-4, etc.) to stain nerve cells and observe changes in intracellular calcium ion concentration using a fluorescence microscope or confocal microscope. Calcium imaging technology can monitor the calcium signals of nerve cells in real time and evaluate the excitability of cells, calcium ion channel activity, and signal transmission function. Changes in the frequency and amplitude of calcium signals can reflect the activity state of nerve cells and synaptic function.

[0063] Synaptic marker staining uses immunofluorescence staining to detect the expression of synaptic markers (such as synapsin, PSD-95, etc.) to evaluate the synaptic connection between nerve cells. Synaptic transmission experiments use electrophysiological recording and calcium imaging technology to detect the synaptic transmission function between nerve cells. For example, evoked postsynaptic currents (EPSCs) are used to record and evaluate the efficacy and strength of synaptic transmission.

[0064] Small molecule probes and fluorescent proteins Use small molecule probes or fluorescent proteins (such as VAMP2-pHluorin) to label synaptic vesicles to monitor the release and recycling process of synaptic vesicles in real time and evaluate the dynamic changes of synaptic function.

[0065] Through these technical means, the functional characteristics of differentiated neural cells can be comprehensively evaluated to ensure that they meet expectations in terms of electrophysiological activity, calcium signaling, and synaptic function. This is crucial for confirming the functional integrity of neural cells and verifying the reliability of neurodegenerative disease models.

[0066] It also includes steps to evaluate multiple drug candidates in constructed disease models through high-throughput screening techniques to identify potential therapeutic drugs.

[0067] Among them, in the constructed neurodegenerative disease model, the efficacy of multiple candidate drugs was evaluated by high-throughput screening technology (HTS). This technology includes specific steps from preparing cell samples, building a candidate drug library, drug treatment, evaluation indicators, data analysis to verification and optimization. It can test the effects of a large number of compounds on nerve cells in a short period of time, quickly identify drugs with potential therapeutic effects, accelerate the process of new drug research and development, and provide a scientific basis for the treatment of neurodegenerative diseases.

[0068] It also includes the use of CRISPR / Cas9 gene editing technology to knock out, knock in, or perform point mutations on specific genes in nerve cells to study gene function with high precision and explore the molecular mechanisms of neurodegenerative diseases.

[0069] Among them, through CRISPR / Cas9 gene editing technology, specific genes can be knocked out, knocked in or point mutated in nerve cells to study gene functions and explore the molecular mechanisms of neurodegenerative diseases with high precision. The specific steps include designing sgRNA and constructing expression vectors, transfecting or transducing the CRISPR / Cas9 system into nerve cells, using Cas9 protein to cut the target gene under the guidance of sgRNA, and achieving gene editing through non-homologous end joining (NHEJ) or homologous recombination repair (HDR). Subsequently, the editing effect is verified by sequencing technology, RT-PCR, Western blot and immunofluorescence staining, and the effects of gene editing on nerve cell function, such as cell survival rate, differentiation state, electrophysiological characteristics, calcium signaling and synaptic function, are evaluated, which not only helps to reveal the pathogenesis of neurodegenerative diseases, but also provides an important tool for the development of gene therapy strategies.

[0070] It will be apparent to those skilled in the art that the invention is not limited to the details of the exemplary embodiments described above and that the invention can be implemented in other specific forms without departing from the spirit or essential features of the invention. Therefore, the embodiments should be considered exemplary and non-limiting in all respects, and the scope of the invention is defined by the appended claims rather than the foregoing description, and it is intended that all variations falling within the meaning and scope of the equivalent elements of the claims be included in the invention. Any reference numeral in a claim should not be considered as limiting the claim to which it relates.

[0071] In addition, it should be understood that although the present specification is described according to embodiments, not every embodiment contains only one independent technical solution. This narrative method of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation methods that those skilled in the art can understand.

Claims

1. A method for constructing a neurodegenerative disease model based on iPSC, characterized in that: include: S1: Obtaining somatic cells from patients with neurodegenerative diseases; S2: reprogramming the somatic cells into iPSCs; S3: amplifying and purifying the iPSCs; S4: differentiating the iPSCs into neural progenitor cells (NPCs); S5: further differentiating the NPCs into specific types of neural cells; S6: verify the type and characteristics of the neural cells; S7: Observe and analyze disease-related phenotypic changes in the neural cells.

2. The method for constructing a neurodegenerative disease model based on iPSC according to claim 1, characterized in that: The somatic cells obtained in step S1 are any one of skin fibroblasts or blood cells.

3. The method for constructing a neurodegenerative disease model based on iPSC according to claim 1, characterized in that: In the S2 step, somatic cells are reprogrammed into iPSCs by introducing OCT4, SOX2, KLF4 and c-MYC reprogramming factors.

4. The method for constructing a neurodegenerative disease model based on iPSC according to claim 1, characterized in that: The reprogramming factors are introduced into the somatic cells via viral vectors or non-viral methods.

5. The method for constructing a neurodegenerative disease model based on iPSC according to claim 1, characterized in that: In the S4 step, iPSCs are differentiated into NPCs by adding neurotrophic factors to the culture medium or forming embryoid bodies through suspension culture.

6. The method for constructing a neurodegenerative disease model based on iPSC according to claim 1, characterized in that: In the step S5, NPCs are differentiated into dopaminergic neurons, motor neurons or astrocytes by regulating the components of the culture medium and adding specific growth factors.

7. The method for constructing a neurodegenerative disease model based on iPSC according to claim 1, characterized in that: In the step S6, the type and characteristics of the neural cells are verified by immunofluorescence staining, RT-PCR and Western blot.

8. The method for constructing a neurodegenerative disease model based on iPSC according to claim 1, characterized in that: In the step S7, the functional properties of the nerve cells are evaluated by electrophysiological recording, calcium imaging and synaptic function detection.

9. The method for constructing a neurodegenerative disease model based on iPSC according to claim 1, characterized in that: The method also includes the step of evaluating a plurality of candidate drugs in the constructed disease model by high-throughput screening technology to identify potential therapeutic drugs.

10. The method for constructing a neurodegenerative disease model based on iPSC according to claim 1, characterized in that: It also includes using CRISPR / Cas9 gene editing technology to knock out, knock in or perform point mutations on specific genes in the nerve cells to study gene functions with high precision and explore the molecular mechanisms of neurodegenerative diseases.

Citation Information

Cited By

  • Gene-environment interaction in-vitro model based on reward pressure stimulation as well as construction method and application of gene-environment interaction in-vitro model

    CN121874114A